These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15060536)

  • 1. Purchase of Aton spotlights HDAC inhibitors.
    Garber K
    Nat Biotechnol; 2004 Apr; 22(4):364-5. PubMed ID: 15060536
    [No Abstract]   [Full Text] [Related]  

  • 2. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
    Riester D; Hildmann C; Schwienhorst A
    Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
    Acharya MR; Sparreboom A; Venitz J; Figg WD
    Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-mercaptoketone based histone deacetylase inhibitors.
    Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
    Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
    J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
    Loudni L; Roche J; Potiron V; Clarhaut J; Bachmann C; Gesson JP; Tranoy-Opalinski I
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4819-23. PubMed ID: 17624773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanism of HDAC inhibitors in anticancer effects.
    Bi G; Jiang G
    Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of novel histone deacetylase inhibitors.
    Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
    Fang JY
    J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
    Kim HM; Lee K; Park BW; Ryu DK; Kim K; Lee CW; Park SK; Han JW; Lee HY; Lee HY; Han G
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4068-70. PubMed ID: 16723227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.